검색어: norbuprenorfina (포르투갈어 - 영어)

norbuprenorfina
norbuprenorphine

norbuprenorfina: auc: ↓ 71
norbuprenorphine: auc: ↓ 71%

auc: ↓ 50% norbuprenorfina:
auc: ↓ 50% norbuprenorphine:

norbuprenorfina: auc: u 71
norbuprenorphine: auc: 0 71%

analgésicos buprenorfina norbuprenorfina metabolitos glucurónidos
ritonavir co-administration is likely to result in increased plasma concentrations of alfuzosin and is therefore contraindicated (see section 4.3) .

norbuprenorfina auc  79% norbuprenorfina cmax  80% norbuprenorfina cmin  80
norbuprenorphine auc  79% norbuprenorphine cmax  80% norbuprenorphine cmin  80%

norbuprenorfina auc ↑105% norbuprenorfina cmax ↑61% norbuprenorfina cmin ↑101
norbuprenorphine auc ↑105% norbuprenorphine cmax ↑61% norbuprenorphine cmin ↑101%

buprenorfina ↑1, 67 ↑1, 37 ↑1, 69 norbuprenorfina ↑2, 05 ↑1, 61 ↑2, 01
buprenorphine ↑ 1.67 ↑ 1.37 ↑ 1.69

devido à redução dos níveis do metabolito ativo norbuprenorfina, a administração concomitante de aptivus, coadministrado com ritonavir em dose baixa, e buprenorfina/naloxona pode resultar numa reduzida eficácia clínica da buprenorfina.
due to reduction in the levels of the active metabolite norbuprenorphine, co-administration of aptivus, co- administered with low dose ritonavir, and buprenorphine/naloxone may result in decreased clinical efficacy of buprenorphine.

• inibidores da cyp3a4: num estudo de interacção da buprenorfina com cetoconazol (um potente inibidor da cyp3a4), observou- se um aumento da cmax e da auc (área sob a curva) da buprenorfina (cerca de 70% e 50% respectivamente) e, em menor escala, da norbuprenorfina.
• cyp3a4 inhibitors: an interaction study of buprenorphine with ketoconazole (a potent inhibitor of cyp3a4) resulted in increased cmax and auc (area under the curve) of buprenorphine (approximately 70% and 50% respectively) and, to a lesser extent, of norbuprenorphine.